Breaking New Ground in Ocular Melanoma Treatment at Replimune | The Eye Believe Podcast

🎙️ Breaking New Ground in Ocular Melanoma Treatment | The Eye Believe Podcast ft. Sush Patel   In this powerful episode of the Eye Believe Podcast, host Danet sits down with 💡 Sush Patel from Replimune to dive into the latest breakthroughs in treating ocular melanoma. 👁️🎗️ This convo is packed with hope, innovation, and insight for patients, caregivers, and advocates alike! 🙌   🔥 What’s Inside: ✨ Game-changing therapies 🧪 Behind the scenes at Replimune 💬 Expert insights from Sush Patel 🌍 What it all means for the ocular melanoma community   Hit that 👍, drop a comment 💬, and subscribe 🔔 to join the movement for awareness and advancement in rare disease care!   *Recorded September 2024 Disclaimer- · RP1 and RP2 are investigational agents which have not been approved or recommended by any regulatory agency and their safety and effectiveness have not been established. · Any discussion of safety and effectiveness of RP2 are based on data observed in the Phase 1 clinical trial most recently presented by Sacco et al. during the 2024 American Society of Clinical Oncology Annual Meeting. Please reference this presentation for the most updated data. · The use of the word product herein means product candidate and is not to be interpreted to be an approved therapy. · The experience of any patient discussed during this interview may not represent the experience of all patients who had received RP2 either alone or in combination with nivolumab. · Please visit https://clinicaltrials.gov/study/NCT06581406 ClinicalTrials.gov Glossary. Study record managers: refer to the Data Element Definitions if submitting registration or results information.. Search for terms clinicaltrials.gov to learn more information about the RP2-202 trial · Speak with your doctor whether a clinical trial is right for you.   #EyeBelievePodcast #OcularMelanoma #CancerAwareness #Immunotherapy #RareDiseaseWarrior #Replimune #CancerBreakthroughs #OncologyUpdates #HopeForOM #HealthInnovation